Document Detail


Rationale for ACE inhibition as an anti-ischaemic therapy.
MedLine Citation:
PMID:  9717054     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Research has established endothelial dysfunction as a pathophysiological mechanism underlying many cardiovascular disease processes. Tissue angiotensin-converting enzyme (ACE) plays a central role in regulating processes that contribute to endothelial function and cardiovascular disease. A number of large clinical studies have demonstrated conclusively the beneficial effects of ACE inhibition in patients with myocardial ischaemia and left ventricular dysfunction, including a significant reduction in the risk of recurrent myocardial infarction. Mechanistic findings from these studies indicated that the beneficial effects of ACE inhibition would extend to patients with preserved left ventricular function. Available results suggest that ACE inhibition with quinapril improves endothelial function in large and small vessels in patients with coronary artery disease and preserved left ventricular function. Quinapril also inhibits progression of coronary atherosclerosis in patients with high levels of low-density lipoprotein cholesterol (> or = 130 mg.dl-1) and reverses the toxic effects of smoking on endothelial function. Endothelial dysfunction also may be an important mechanism in episodes of angina and silent ischaemia. The central role of tissue ACE in endothelial function suggests that ACE inhibition has antiischaemic effects. A study in progress, the QUinapril Antiischaemia and Symptoms of Angina Reduction trial, addresses shortcomings in earlier studies of ACE inhibition for ischaemia and is expected to define the role of quinapril in ischaemia.
Authors:
C J Pepine
Related Documents :
22877804 - Usefulness of high-sensitivity troponin t for the evaluation of patients with acute che...
15330734 - A review of the angiotensin-converting enzyme inhibitor, zofenopril, in the treatment o...
12052274 - New biomarkers in the risk stratification of patients with suspected acute myocardial i...
15570784 - Pharmacological prevention of cardiac risk in claudicants with ischaemic heart disease.
11304104 - Treatment of patients with myocardial infarction who present with a paced rhythm.
6485874 - Cardiac dysrhythmias in patients with acute myocardial infarction. relation to serum po...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  European heart journal     Volume:  19 Suppl G     ISSN:  0195-668X     ISO Abbreviation:  Eur. Heart J.     Publication Date:  1998 Jul 
Date Detail:
Created Date:  1998-12-03     Completed Date:  1998-12-03     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8006263     Medline TA:  Eur Heart J     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  G34-40     Citation Subset:  IM    
Affiliation:
University of Florida College of Medicine, Gainesville 32610-0277, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin-Converting Enzyme Inhibitors / adverse effects,  therapeutic use*
Cholesterol, LDL / blood
Coronary Artery Disease / drug therapy,  mortality
Coronary Disease / drug therapy*,  mortality
Endothelium, Vascular / drug effects
Humans
Isoquinolines / adverse effects,  therapeutic use*
Myocardial Ischemia / drug therapy*,  mortality
Randomized Controlled Trials as Topic
Survival Rate
Tetrahydroisoquinolines*
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Cholesterol, LDL; 0/Isoquinolines; 0/Tetrahydroisoquinolines; 82586-55-8/quinapril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Altered regulation of smooth muscle cell proliferation and apoptosis in small arteries of spontaneou...
Next Document:  Endothelial function and dysfunction in heart failure.